Spectral AI, Inc. (MDAI) Earnings Call Transcript
March 24, 2026
Earnings Call Speaker Segments
Thanks, Gary. Hello, everybody, and I appreciate you being with us this afternoon for Spectral AI's conference call covering our financial results for 2025's fourth quarter as well as the entire year. Joining us as speakers today are Vincent Capone, who serves as the company's Chief Executive Officer, along with Thomas Spieth, our Corporate Controller. Prior to getting started, I want to remind all of you that on this call, a number of statements we make are forward-looking statements as defined under the Safe Harbor provisions of the United States Private Securities Litigation Reform Act of 1995, and these include statements about the company's strategy, plans, objectives, initiatives, and financial outlook. On this call, terms such as estimates, projected, expects, anticipates, forecasts, plans, intends, believes, seeks, may, will, should, future, propose, plus variations of those terms or similar expressions, or the negative forms of such terms or expressions, are meant to signal forward-looking statements; such forward-looking statements do not constitute guarantees of future performance, conditions, or results and carry a number of known and unknown risks, uncertainties, assumptions, and other important factors, many beyond the Company's control, which might cause actual results or outcomes to differ materially from those covered in the forward-looking statements. Accordingly, listeners are warned against placing undue reliance on any forward-looking statements. Investors ought to carefully weigh the aforementioned factors along with the other risks and uncertainties set forth in the Risk Factors section of the Company's filings with the SEC, including the registration statement and other documents the Company has filed. Those filings identify and address additional important risks and uncertainties that might cause actual events and results to differ materially from those contained in the forward-looking statements. Having said that, I would now like to hand the call over to Vincent Capone, Spectral AI's Chief Executive Officer. Vince, please go ahead.
Appreciate that, Devin, and thanks to everyone for being on the call today. Our earnings release went out this afternoon, and it includes further specifics about how we performed operationally. Later on this evening, we'll also be filing our 10-K with the SEC. My comments today will center on the year-end review and what's happening on the corporate side, and Tom Spieth, our Controller, will walk everyone through the main financial metrics. After that, we'll open things up for questions. For Spectral AI, 2025 was a pivotal year, one in which we advanced considerably on multiple fronts as we pursue our chief objective of bringing the DeepView system to market for the burn indication. DeepView is a diagnostic tool that gives medical personnel the ability to make fast, data-driven calls about whether a burn wound will heal by itself or whether it will need significant medical intervention. That unmet clinical need becomes dramatically larger when a mass casualty burn incident occurs, since being able to triage burn patients quickly and correctly would be essential for allocating precious resources and handling the surgical burden. Our DeepView System is built to help the U.S. government get ready for any such mass casualty event. Many of you probably know that the defining moment for our company came in June 2025, when we submitted our De Novo application to the FDA. That submission represented the culmination of years of effort from our talented, hardworking, and dedicated team. After we submitted it, and as we had anticipated, an additional information notification letter arrived from the FDA, and we responded to it fully and on time earlier this month. We continue to keep an active dialogue going with the FDA, and the feedback we've gotten has matched what we expected. We're hopeful that the FDA will respond positively before the second quarter of this year comes to an end; now, turning to a review of 2025. In March 2025, we finished our burn validation study. This 15-month trial is among the biggest burn studies ever conducted in the U.S., pulling in data on 164 adults and children from 15 burn centers and emergency rooms nationwide. Within that trial, the DeepView system outperformed burn doctors' clinical judgment by a wide margin. After securing the FDA clearance we're anticipating, we'll kick off an outcomes study to measure how much DeepView actually changes things in real hospital practice. That next study will zero in on gains for patients throughout their care journeys and for clinician workflows. Results from the burn validation work were submitted as part of our De Novo filing with the FDA. Taking a step back, placing our DeepView System in those burn units and ERs helped spread word about the technology to a broader set of people who might eventually use the device, assuming it secures FDA clearance down the road. So you can picture the size of this opportunity: roughly 125 burn centers exist nationwide, alongside 700 trauma centers, plus 5,400 federal and community hospitals operating emergency rooms — and those ERs are typically the first place burn victims land after getting hurt. Switching gears, I'd like to discuss our BARDA contract; we've held a lasting, major, and robust alliance with the Biomedical Advanced Research and Development Authority going back to 2013. The support they've given us has been instrumental in advancing our product to this point, particularly regarding the Project BioShield agreement we entered into back in September 2023, which carries a potential value of $150 million. From that total, $55 million came through right away under the contract's initial phase. Thanks to this BARDA funding, we've been able to move product development forward, and it has additionally covered a wide range of U.S.-based studies designed to confirm the effectiveness of our DeepView technology along with our AI algorithm across emergency departments, trauma centers, and burn centers. As was shared last week, BARDA has once again shown its dedication to the DeepView system's development, granting Spectral AI $31.7 million in advanced funding so we can speed up and back further feature elements of our cutting-edge AI-powered diagnostic device. Alongside that award, we've pledged another $9.7 million of our own to cover the full development expenses tied to these improvements. Pushing ahead with phase two of our BARDA contract means we can progress more quickly on additional work for the DeepView System — above all, our tool for measuring total body surface area and our EHR integration. There's also a clause in our BARDA agreement: if the FDA approves our device, BARDA can help fund an initial round of sales and distribution covering as many as 30 DeepView Systems placed in burn centers located in major U.S. regions. Under the same agreement, BARDA may provide additional support for 140 more DeepView Systems going into burn centers and level 1 trauma emergency departments throughout the country. Outside the U.S., the DeepView Systems we've installed in the United Kingdom have drawn favorable responses from users. And as we've mentioned before, we secured UKCA authorization for the burn indication back in 2024. Once the FDA gives us a favorable decision on our De Novo submission in 2026, our UKCA authorization will be revised so that it covers the enhanced DeepView system in the same form we filed with the FDA. With that broader UKCA clearance in hand, we expect the first revenue from sales in the U.K., Australia, or the Gulf Cooperation Council countries to arrive late in 2026. Even though a handover period will follow the FDA approval we're anticipating, 2026 is when we'll truly launch commercial operations, drawing on the manufacturing partnerships we already have and growing our sales force so we can complete the first commercial sales in our company's history. In our view, the plan we have positions us to achieve swift uptake in the market, both within and beyond our BARDA relationship. At this point, I'd also like to provide a few extra details regarding our handheld device, which is still being developed under our Department of Defense contract via the contracting consortium known as MTEC; during late 2025, we executed a no-cost extension of our existing phase II contract, simply pushing it out to June 30, 2026. In line with what our present contract calls for, we expect to deliver a completely functional prototype of the handheld device before the second quarter of 2026 concludes. Following that point, we will also figure out whether any further scope items can be finished under that contract prior to the close of the third quarter of 2026. Phase II of the MTEC contract is expected to go through review and award before Q4 2026 wraps up, and we're hoping that opens the door for us to bid on that work. Beyond that, we anticipate leveraging whatever FDA clearances come through for the cart-based DeepView system as a predicate for the handheld version. After that point, our plan is to pursue 510(k) clearance for the handheld device, once the approvals now under FDA review for the cart-based DeepView system are in hand. Before I hand things to Tom, I'm glad to report that we came into 2026 with the strongest liquidity and financial standing in our recent history, and definitely throughout the time I have spent with this company. Our cash position, which exceeded $15 million at year-end, was three times what it was on December 31st, 2024, and we have brought our operating expense profile into line with our strategic priorities. That gives us the ability to chase our growth objectives both before approval and, hopefully, after approval from a place of strength and with enough cash runway. Although I have taken part in many calls previously, I also want to note that this marks my first call in the role of the company's Chief Executive Officer. I'd like to express thanks to the board for their ongoing confidence in me, and to the incredible group of people I am lucky enough to work alongside daily. They are the ones propelling our success. I feel grateful to guide Spectral toward bigger and better things. Having said that, I will now hand the conference call over to Tom for a look at our financial results.
Thanks, Vince. Like Vince mentioned, we enjoyed a solid year and feel we now have the financial results in place to keep funding our R&D work and grow into a commercial operation. Starting with Q4, R&D revenue for the fourth quarter of 2025 came in at $3.8 million, versus $7.6 million, which mirrors the expected drop in research direct labor, clinical trial, and other reimbursed study costs compared with 2024, as the company got nearer to wrapping up the base phase under our contract with BARDA. We refer to it as the BARDA PBS contract. Gross margin for Q4 2025 stood at 39.8% versus 44.0%, mainly because reimbursed direct labor made up a smaller share of total revenue from the BARDA PBS contract. G&A expenses for Q4 2025 totaled $4.0 million, a decrease from $4.5 million in Q4 2024, driven by reduced spending on third-party accounting and legal providers. Net income for Q4 2025 reached $0.6 million, or $0.02 per diluted share, against a net loss of $7.7 million, or negative $0.41 per diluted share, in the fourth quarter of 2024. Net income in Q4 2025 included a $4 million gain in the fair value of the company's warrant liability, compared with a net loss of $5.4 million; now let's move to the full year. Research and development revenue fell to $19.7 million from $29.6 million, mirroring the expected overall decrease in the company's reimbursed costs tied to the BARDA PBS contract during 2025, after the company submitted its De Novo application to the FDA. Gross margin held steady at 45.4% versus 44.9%, reflecting a consistent mix of direct labor as a share of the total work performed on the BARDA PBS contract compared with the prior year. G&A dropped to $17.5 million from $19.9 million, reflecting a continued emphasis on operating efficiencies at the company. Our net loss for the year was $7.6 million, or negative $0.29 per diluted share, against a net loss of $15.3 million, or negative $0.85 per diluted share, primarily due to the change in the fair value of the company's warrant liability, reduced borrowing-related costs of $1.5 million, net amortization of debt discount, and improved operating efficiencies. As of December 31st, 2025, we had roughly 30.7 million shares outstanding; regarding our financial condition, as of December 31st, 2025, cash improved to $15.4 million from $5.2 million at December 31st, 2024, reflecting previously announced debt and equity financings completed during the year as well as warrant and stock option exercises. Total debt was $8.5 million. I'll now hand the call back to Vince.
Appreciate that, Tom. Ahead of handing the call to Q&A, I want to cover what we expect in 2026. Our projection for 2026 puts revenue at roughly $18.5 million, and that figure factors in the impact of the new BARDA funding; no meaningful contribution from DeepView system sales is baked into this guidance; so with that said, I'll now take any questions.
Hello there. I appreciate you answering our questions. First off, congratulations on the BARDA funding, and Vince, on your new position. Perhaps, since we're considering your move into a commercial organization this year, Vince, could you share a bit about how you're approaching readiness for commercialization—what steps are needed to prepare the organization to operate as a commercial entity, and so on? I have some follow-ups after that.
Of course. Nice to hear from you, Ryan. So, there are several items we're addressing to get ready for what we hope will be FDA approval. Among them, we've already begun looking for a new Chief Commercial Officer. We've also brought in Deloitte Consulting to assist with our strategic plan for commercialization going forward, covering both the U.S. and international markets. That work is already in progress. We still have initiatives planned to grow our sales team. I'd prefer to do that alongside bringing on a new Chief Commercial Officer. That ought to put us in a spot where we're prepared to see sales both within and beyond BARDA in late 2026.
To make sure we're on the same page, let's suppose approval arrives on schedule. Regarding those 30 systems going out to burn centers across the U.S., what's your thinking on the commercial activity that comes out of that? Since you might not actually be selling those systems — perhaps because, again, BARDA is the one distributing them — how do you view what that means for the business model, or what should investors expect from that as time goes on?
In the end, every health system is going to decide for itself how it prefers to handle the device, assuming we're able to install it at their facilities, correct? Purchase versus lease makes a difference on our end — revenue recognition differs from a company standpoint. We anticipate a chance to be situated at every center where we can put a device, ideally under a three-year agreement covering both, you know, software enhancements and software licensing, plus providing device maintenance. You bundle all of that together. Once more, it comes down to the health system and how we as a company account for that revenue stream. We believe our position is strong. For 2026, I don't expect this to contribute much to our revenue figure, though it will clearly matter a great deal in 2027, and even more so in 2028, when you get the stacking of every tier of installations.
All right. So with that fresh BARDA agreement — which, honestly, it was wonderful to see, and we weren't anticipating it, we definitely weren't anticipating guidance like this, which is fantastic, and once more, quite encouraging looking ahead to 2026 — what sorts of items will you be tackling using these extra funds from BARDA to strengthen DeepView? That, as I picture it, means you must be accelerating certain efforts, perhaps bringing some chances ahead of schedule, simply because of the development revenue you're now receiving under this agreement. What impact does that have on DeepView if, a year from today, we're examining a few of the capabilities and a few of the investments you've completed across 2026?
Yes. That's a question I really enjoy. There are so many items that, as we see it, are sort of within reach. A label expansion is something we'll be pursuing. My guess is that will likely be among the earliest items you'll notice, and there we'll be adding various regions of the body. We'll aim to pursue a label expansion. Additional effort is coming on our TBSA, total body surface area, product to make it, as you know, superior for the doctors, superior for the physician assistants, superior for the nurses. That's a process we've devoted considerable work toward to bring it to where it is now, and it forms part of our FDA submission. The upcoming version of that will be considerably improved. The version following that one, should one exist, will be improved still further. Fold that together with enhanced EHR integration. At a minimum, we're likewise addressing matters we've been told about by other users. As you know, the battery is something we'll be upgrading. A few of the user interfaces are things we'll be upgrading. This fine-tuning, in my view, will render our device all the more valuable inside a burn center.
That's really useful, and congratulations once more, everyone. Good to see.
Thank you, Ryan. I appreciate that.
I appreciate you taking the question, and once more, congratulations on the BARDA advance — especially with DeepView's approval still ahead. And Vince, congrats to you as well on the promotion and the new position. Regarding that $31.7 BARDA advance, I'd like to know if you could share some sense of how you see it landing in 2026 and 2027, and likewise for the roughly $63 million left on the contract when it comes to filling CLIN 2, CLIN 3, and CLIN 4 — I'd call those obligations, but the buckets span fiscal 2026, 2027, and 2028. That's a big ask, I realize, but whatever visibility you could offer would be terrific. Thank you.
Thank you, Carl. Well, we're obviously happy that BARDA chose to speed up the contract's second phase ahead of FDA approval. They've proven a valued partner and, honestly, a very supportive one for us. This accomplishes several things on our behalf; it will create the chance for us. Should we secure FDA approval, we could truly get going on producing devices with the new De Novo system in place, and genuinely begin working with hospital systems to place these devices. That's, you know, a piece of what the contract acceleration involves. I'm not able to delve too deeply into the contract's specifics regarding what it will accomplish in 2028. We have, you know, we have health economic studies lined up that we intend to conduct. You know, we also have expanded label work that we'll carry out in-house, you know, to broaden our label regarding what the indication covers. There are outcome studies we're going to launch in earnest before too long. All of this benefits us as an acceleration and puts us in position, you know, to reach the point where we can deliver better outcomes for burn patients and offer a superior alternative, so we can help the healthcare system be positioned to treat these patients more promptly and more efficiently.
That went really well. Thanks a lot. Congratulations once more.
Appreciate it, Carl.
I appreciate the opportunity to ask a few things. I'll keep it to 3 quick items. First, could you remind everyone of the schedule over which you expect the full amount of BARDA money to be paid out? Second, I'd like to know how you plan to handle tweaking or updating your revenue outlook once the DeepView system receives FDA licensure. Finally, regarding possible ways to maximize what DeepView is worth beyond the U.S., I was hoping you might offer a few comments. Thank you.
Certainly. Glad to address those. That's 3 fairly wide-ranging items, so let's sort of go through them. The BARDA contract itself, as I understand it, runs through 2030. When you consider the acceleration, most of that occurs through 2028; this agreement will benefit our revenue sooner rather than later. You know, it. That's the schedule for the whole BARDA contract. Down the road, as matters develop, that schedule could be pulled forward, but you know, those are the provisions of the BARDA contract itself. There will be an acceleration through 2028. On updating and adjusting our revenue projection: as I told Ryan, you know, part of this hinges on health systems and their preferences regarding how the device actually gets deployed. Whatever approach they choose will significantly affect when we recognize revenue. From our standpoint, putting a unit into a burn center is clearly a key milestone, even when revenue gets recognized, let's say, across a 36-month span. Combine that with the software licensing element, which will serve them well as we roll out enhancements, and you'll observe that sort of accumulation of installations during 2027 and 2028 as we advance along the sequence of installations in burn centers, EDs, and level 1 trauma centers alike. That applies both inside and outside BARDA. I want to be quite clear on that point. I mean, we intend to commercialize this in the United States with BARDA's help, though not only and exclusively via BARDA's help; the same holds true regarding our opportunities for international sales in the U.K., the GCC, and Australia. We will amend our UKCA authorization so it covers what's in the present DeepView system, the one undergoing De Novo review with the FDA. Once that happens, we'll shift course and aim to place those devices in overseas markets. That revenue model could look different, given how those health systems—some of them state-run—choose to handle sales of DeepView systems in other countries. Again, I place limited weight on those figures for 2026. They could be bigger, yet you'll see more of that emerge as a clearly larger revenue component in 2027 and in 2028.
Thank you.
Thank you.
Thanks. Hey, Vince. How is the training team shaping up, and what's your approach for getting the trainers ready? My assumption is you'll send out a crew to bring everyone up to speed on operating these things during the implementations.
John, great to hear from you. As you know, we've got a team — a pretty solid crew of BMEs already here — and we intend to grow it. That's included in the 2026 budget: growing both our sales reps and our biomedical engineers right here at Spectral. It'll be a joint effort between the BMEs and our sales team to ensure we're out there teaching plenty of these centers how to operate the device once they receive it. The device — and I realize you've already looked at it, but I'll describe it for those who haven't — is intuitive. There's a queue in place so the image capture happens at the proper distance. We're also developing several other features to make it even easier for users. Yes, growing our training team will be necessary. That's our plan; we also intend to grow our sales team. I'm simply thrilled about how the company finished 2025. Our cash figure is substantial. In my view we're in the strongest financial shape we've ever had, particularly across my time here, which is now in my fifth year. I'm enthusiastic about what we've got and where we're headed, and we'll pair our training team with the growth we're pursuing.
Is there a figure you've settled on for the count of people who would need training?
Not a specific one. That said, I do have a rough figure in my head. What we're discussing isn't in the hundreds. The count we're discussing is significantly below that. Still, it makes me happy that we're collaborating with Deloitte Consulting to ensure our way ahead is the correct one.
All right. Once you've got clearance, how long do you figure it will be before the first units are placed?
John, I wish I had a crystal ball, right? The only thing I know is that manufacturing the devices is going to take us a little while. But, you know, my hope — and we've said this before — my hope is that in late 2026 we place devices, and you'll see a significant pivot in 2027.
The final thing I want to ask about is how you're thinking ahead when it comes to where R&D dollars get directed. I realize Snapshot is in the picture. There are a few signals beyond burn. And you've also mentioned how the DeepView cart might evolve down the road, plus, I suppose, work on artificial intelligence or simply the AI and machine learning area. As you look toward the coming year, maybe 2027, and past that, how would that split up in terms of R&D spending?
What I can say is that a label expansion covering head, hands, and feet is absolutely something we will pursue. That is certainly going to happen. We examine quite a few possibilities available to us. Several of them are coming our way from outside companies. In my view, the easiest win is the label expansion and the effort behind it. Another indication could emerge, be it critical limb ischemia and associated matters, be it amputations, or be it a partnership with, say, a wound care firm to examine biofilm markers or wound bed preparedness. As you know, we keep viewing that as a nearer-term extra indication. Still, look, we're thrilled with how 2025 turned out for us; we're thrilled about BARDA's commitment to us involving an extra nearly $32 million; we're thrilled to deliver this to the burn community and then grow from there.
Okay. Thank you. Thank you, Vince.
Thanks, John.
Gary, thank you. To wrap up, I want once more to express appreciation to those who have invested in us for standing behind this business. It's thrilling to fulfill what we promised — building and bringing to market the DeepView system — which, in our view, will meaningfully better the results patients experience. Given the solid cash we hold and the ongoing progress we're making on creating our products, I feel good about our present standing and about what lies just ahead. Thanks to each of you for joining us and for caring about this company. Enjoy your evening.
That brings us to the end of this call. We appreciate your participation in the presentation today. You're welcome to leave the line now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Spectral AI, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Spectral AI, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.